GenePOC announces product launch in Europe and Middle East

Québec, Canada/Lausanne, Switzerland (ots) - GenePOC announces the
commercialization of its Clostridium difficile and Group B Strep
molecular tests in Europe, along with onboarding additional partners
to cover the EMEA market

GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is proud to
announce that it has started the commercialization of its first two
CE-IVD marked tests, GenePOC(TM) CDiff and GenePOC(TM) GBS assays on
the revogene(TM) platform that recently obtained CE-IVD marking. In
addition to the distribution partners across all major markets in
Europe announced earlier, distribution agreements have been signed
with Sedeer Medical, Headquarters in Qatar, and Bühlmann Laboratories
in Switzerland. GenePOC has today commercial reach across Europe and
the Middle East for the commercialization of its first products. This
is a key milestone in the evolution of GenePOC's commercial
operations.

"The GenePOC CDiff test will fulfill the increasing market need for
affordable, fully automated and easy to use testing at Point of Care
as early detection of C. difficile can lead to better control and
management of the infection, which in turn can improve patient
health, reduce the risk of transmission, and potentially lower
mortality and morbidity", Patrice Allibert CEO of GenePOC commented.
"We are also delighted to start our commercialization with the
signing of these additional collaborations. We have seen first-hand
the enthusiasm of our partners during our first distributors' meeting
in Q4 of 2016 and in recent pre-launch interactions. We expect the
combination of exceptional products and partners to lead to rapid
adoption of the revogene(TM) platform", he continued.

The commercial partners signed up today are Astra Formedic S.r.l. in
Italy, bestbion dx GmbH in Germany/Austria, Biosynex Group in France,
EMM Life Science AB in Sweden/Denmark/Finland/Nor-way/Iceland, Fannin
Ltd in Ireland, Mediphos Group BV in Netherlands/Belgium/Luxembourg,
Near Patient Diagnostics Ltd in the UK, Vitro S.A.B. de C.V. in
Spain/Portugal, Sedeer Medical direct or through partners in Qatar,
Iran, United Arab Emirates, Bahrain, Kuwait and Oman, and Bühlmann
Laboratories in Switzerland. Negotiations are ongoing for those
countries not listed yet and GenePOC expects to sign on additional
distributors in the coming months to best serve customers initially
in the EMEA region and later in the year globally.

About GenePOC

GenePOC(TM) is a company that specializes in the development of rapid
diagnostic devices which enable the prevention and detection of
infectious diseases. GenePOC is a member of the Debiopharm Group.

The company devised the GenePOC Diagnostics system, enabling rapid
microbial testing at the point of care (POC). The revogene(TM)
instrument can analyze any type of infection in no more than an hour,
is easy to operate and deals with a wide range of biological samples,
making it a user-friendly and efficient tool.

Further information: www.genepoc-diagnostics.com/

About Debiopharm Group

Debiopharm Group(TM) is a Swiss-headquartered global
biopharmaceutical group of five companies active worldwide in the
development and manufacture of drugs and diagnostic tools. Debiopharm
focuses on developing prescription drugs and diagnostics that target
unmet medical needs. The group in-licenses and develops promising
drug candidates. The products are commercialized by out-licensing
partners and distribution partners to give access to the largest
number of patients worldwide.

For more information, please see www.debiopharm.com

We are on Twitter. Follow @DebiopharmNews at
http://twitter.com/DebiopharmNews

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EUN

print